Laboratory of Chemical Biology and Institute for Complex Molecular Systems (ICMS), Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands.
Chemical Biology, Center of Medical Biotechnology, Faculty of Biology, University of Duisburg-Essen, Duisburg, Germany.
Nat Commun. 2020 Aug 7;11(1):3954. doi: 10.1038/s41467-020-17741-0.
The systematic stabilization of protein-protein interactions (PPI) has great potential as innovative drug discovery strategy to target novel and hard-to-drug protein classes. The current lack of chemical starting points and focused screening opportunities limits the identification of small molecule stabilizers that engage two proteins simultaneously. Starting from our previously described virtual screening strategy to identify inhibitors of 14-3-3 proteins, we report a conceptual molecular docking approach providing concrete entries for discovery and rational optimization of stabilizers for the interaction of 14-3-3 with the carbohydrate-response element-binding protein (ChREBP). X-ray crystallography reveals a distinct difference in the binding modes between weak and general inhibitors of 14-3-3 complexes and a specific, potent stabilizer of the 14-3-3/ChREBP complex. Structure-guided stabilizer optimization results in selective, up to 26-fold enhancement of the 14-3-3/ChREBP interaction. This study demonstrates the potential of rational design approaches for the development of selective PPI stabilizers starting from weak, promiscuous PPI inhibitors.
蛋白质-蛋白质相互作用(PPI)的系统稳定化具有作为创新药物发现策略的巨大潜力,可以靶向新型和难以成药的蛋白质类别。目前缺乏化学起点和有针对性的筛选机会,限制了同时结合两种蛋白质的小分子稳定剂的鉴定。本研究从我们之前描述的用于鉴定 14-3-3 蛋白抑制剂的虚拟筛选策略出发,报告了一种概念性的分子对接方法,为发现和合理优化 14-3-3 与碳水化合物反应元件结合蛋白(ChREBP)相互作用的稳定剂提供了具体的切入点。X 射线晶体学揭示了弱抑制剂和通用抑制剂与 14-3-3 复合物之间以及特定、强效的 14-3-3/ChREBP 复合物稳定剂之间的结合模式的明显差异。基于结构的稳定剂优化导致 14-3-3/ChREBP 相互作用选择性增强高达 26 倍。这项研究证明了从弱、广谱的 PPI 抑制剂开始,通过合理设计方法开发选择性 PPI 稳定剂的潜力。